Unlabelled: INTRODUCTION Inter-institutional re-review of prostate needle biopsy (PNBx) material is required at many institutions before definitive treatment, but adds time and cost and may not significantly alter urologic management. We aim to determine the utility of universal PNBx re-review on influencing the decision to recommend definitive local therapy for patients with prostate cancer.
Materials And Methods: From 2017-2020, 590 prostate biopsy specimens from outside institutions were re-reviewed at our center for patients considering prostatectomy. Clinical and pathologic characteristics from initial and secondary review were analyzed. Potential for change in treatment candidacy (CTC) was determined by re-diagnosis to non-malignant tissue or change in candidacy for active surveillance (AS) versus definitive treatment (i.e. prostatectomy or radiation therapy). Thus, the following scenarios were considered CTC: downgrading to non-malignant tissue, downgrading ISUP Grade Group (GG) ≥ 2 to GG1, and upgrading GG1 to GG ≥ 2. Any changes between GG2 to GG5 were not considered CTC, as definitive treatment would be offered to all groups.
Results: Overall, 55 patients (9.3%) had potential for CTC based on secondary review, all of whom had initial pathologic GG (iGG) ≤ 2. Of the 152 patients with iGG1, 8 were downgraded to no malignancy and 41 were upgraded to GG2 or GG3. Of the 185 patients with iGG2, 6 were downgraded to GG1. No patients with iGG ≥ 3 qualified for a CTC. Features associated with CTC included iGG, number of positive cores, and highest core percentage. Upon multivariable analysis, only iGG1 diagnosis was predictive of CTC (OR 23.66, p < 0.001).
Conclusion: Second review may be helpful in determining need for definitive treatment in patients with GG1 and GG2 prostate cancer, i.e. those considering AS. This process appears unnecessary in GG3+ patients, as management for patients considering surgery would not change. This may allow for judicious redirection of hospital resources.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Deep sequencing-derived Metagenome Assembled Genomes from the gut microbiome of liver transplant patients.
Sci Data
January 2025
Department of Food Science and Human Nutrition, University of Illinois at Urbana-Champaign, Urbana, IL, 61801, USA.
Recurrence of metabolic dysfunction-associated steatotic liver disease (MASLD) after liver transplantation (LT) is a continuing concern. The role of gut microbiome dysbiosis in MASLD initiation and progression has been well established. However, there is a lack of comprehensive gut microbiome shotgun sequence data for patients experiencing MASLD recurrence after LT.
View Article and Find Full Text PDFImportance of infarct topography in determination of stroke mechanism and recurrence risk: a post-hoc analysis of the dabigatran acute treatment of stroke trial.
BMJ Open
January 2025
School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, New South Wales, Australia
Objective: To evaluate the relationship between infarct pattern, inferred stroke mechanism and risk of recurrence in patients with ischaemic stroke. The question is clinically relevant to optimise secondary stroke prevention investigations and treatment.
Design: We conducted a retrospective analysis of the dabigatran treatment of acute stroke II (DATAS II) trial (ClinicalTrials.
[Interventional studies on acute-on-chronic liver failure: challenges and opportunities].
Zhonghua Gan Zang Bing Za Zhi
December 2024
Fourth Department of Liver Disease, Beijing Youan Hospital, Beijing100069, China Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing100069, China.
Acute-on-chronic liver failure (ACLF) is a kind of complex syndrome characterized by acute deterioration of liver function on the basis of chronic liver disease, accompanied by organ failure and a high mortality rate. The International Society for Hepatology has proposed different definitions, diagnostic criteria, and treatment guidelines, which have led to differences in the clinical management of ACLF and underestimated the burden of the disease. Currently, there is no specific treatment for ACLF, and the overall prognosis is still not ideal.
View Article and Find Full Text PDFEmphysema or fibrosis progression in patients with combined pulmonary fibrosis and emphysema.
Am J Med Sci
January 2025
Department of Pulmonary and Critical Care Medicine, Dongying People's Hospital, Dongying, Shandong, China. Electronic address:
Background: Patients with combined pulmonary fibrosis and emphysema (CPFE) may experience emphysema or fibrosis progression on chest computed tomography (CT). This study aimed to investigate the relationship and prognosis in CPFE patients with emphysema or fibrosis progression.
Methods: A total of 188 CPFE patients were included in our retrospective cohort study.
Validation of a non-invasive filling pressure (NIFP) device for measuring cardiac pressure and assessing congestion levels in patients with heart failure.
Int J Cardiol
January 2025
State Key Laboratory for Innovation and Transformation of Luobing Theory, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. Electronic address:
Background: Heart failure (HF) is a high-burden clinical syndrome characterized by intravascular and extravascular congestion, impacting patients' outcomes. Current diagnostic methods for assessing intravascular congestion, including right heart catheterization (RHC), have some limitations. There is a need for accurate, stable, and widely applicable non-invasive measurement methods to improve HF diagnosis and treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!